Last 47 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.97 | 0.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.28 | 0.22 | — | — | 138.65 | — | — | — | — | — | — | 433.27 | — | — | — | — | 1031.77 | 634.17 | 30.09 | 1407.06 | 204.76 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +403.9% | +321.7% | -46.5% | — | — | |
| P/B Ratio | 5.69 | 1.02 | 13.49 | 5.42 | 3.62 | 2.30 | 1.95 | 1.20 | 1.53 | 5.08 | 4.98 | 3.86 | 3.68 | 3.67 | 4.24 | 4.11 | 2.61 | 1.46 | 1.64 | 1.76 | 2.38 |
| — | -55.8% | +590.3% | +351.3% | +136.9% | -54.8% | -60.7% | -68.9% | -58.4% | +38.7% | +17.3% | -6.2% | +41.0% | +151.0% | +158.2% | +133.7% | +9.7% | -26.6% | -17.0% | -24.7% | -27.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.03 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | -0.14 | -0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | -0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | 100.0% | — | — | — | — | — | — | -145.7% | — | — | — | — | -391.1% | -300.0% | 85.4% | -495.7% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -491.1% | -400.0% | -14.6% | — | — | |
| Operating Margin | -40274.4% | 78.8% | — | — | -6324.4% | — | — | — | — | — | — | -12769.1% | — | — | — | — | -21775.6% | -17444.4% | -549.4% | -34991.3% | -2776.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -684.3% | -814.3% | +36.4% | — | — | |
| Net Margin | -37652.2% | 79.7% | — | — | -5701.1% | — | — | — | — | — | — | -11511.1% | — | — | — | — | -21053.3% | -17260.0% | -545.6% | -34826.1% | -2756.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -663.7% | -814.4% | +36.2% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.0% | 171.1% | -108.9% | -55.0% | -31.3% | -30.8% | -54.5% | -18.7% | -28.2% | -25.9% | -21.6% | -23.3% | -27.5% | -27.5% | -17.8% | -15.5% | -12.7% | -10.6% | -7.2% | -10.4% | -8.0% |
| — | +656.2% | -99.8% | -193.1% | -11.0% | -18.8% | -152.3% | +19.6% | -2.7% | +5.9% | -21.1% | -50.8% | -116.6% | -160.6% | -147.7% | -48.5% | -58.7% | -59.1% | +10.6% | +12.9% | +30.6% | |
| ROA | -52.7% | 65.2% | -11.4% | -11.0% | -8.6% | -10.4% | -21.9% | -8.4% | -13.5% | -12.7% | -10.2% | -10.9% | -14.1% | -15.1% | -10.2% | -9.2% | -7.9% | -7.9% | -6.6% | -9.7% | -7.6% |
| — | +724.0% | +48.1% | -31.6% | +36.0% | +18.0% | -114.5% | +23.6% | +4.7% | +15.6% | -0.0% | -18.7% | -77.9% | -90.9% | -54.2% | +5.1% | -4.4% | -25.7% | +12.0% | +11.0% | +26.9% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.04 | 0.66 | 0.22 | 0.08 | 0.07 | 0.06 | 0.05 | 0.04 | 0.04 | 0.05 | 0.06 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.00 | 0.00 | 0.01 |
| — | -34.8% | +1082.1% | +350.3% | +85.2% | +60.8% | +23.4% | -17.3% | -11.7% | -4.2% | +5.1% | +49.6% | +39.0% | +30.0% | +1402.5% | +821.1% | +596.1% | +415.4% | -68.1% | -65.0% | -72.8% | |
| Debt / EBITDA | — | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.20 | 4.08 | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 | 9.87 | 10.44 | 12.53 | 10.44 | 13.58 | 18.83 | 12.94 | 11.66 | 19.87 |
| — | -44.5% | -37.0% | -32.2% | -22.4% | -18.0% | -11.7% | -0.8% | +3.9% | -14.3% | -15.5% | -11.7% | -27.3% | -44.6% | -3.2% | -10.5% | -31.6% | -12.3% | -26.9% | -14.4% | +89.1% | |
| Quick Ratio | 6.20 | 4.08 | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 | 9.87 | 10.44 | 12.53 | 10.44 | 13.58 | 18.83 | 12.94 | 11.66 | 19.87 |
| — | -44.5% | -37.0% | -32.2% | -22.4% | -18.0% | -11.7% | -0.8% | +3.9% | -14.3% | -15.5% | -11.7% | -27.3% | -44.6% | -3.2% | -10.5% | -31.6% | -12.3% | -26.9% | -14.4% | +89.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ATNM stock.
Actinium Pharmaceuticals, Inc.'s current P/E is 4.0x. The average P/E over the last 1 quarters is 0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Actinium Pharmaceuticals, Inc.'s current operating margin is -40274.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Actinium Pharmaceuticals, Inc.'s business trajectory between earnings reports.